Shares of Silk Road Medical Inc (NASDAQ:SILK) have earned an average broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.

Brokers have set a one year consensus target price of $44.00 for the company and are expecting that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also assigned Silk Road Medical an industry rank of 107 out of 256 based on the ratings given to its competitors.

A number of analysts recently weighed in on SILK shares. JPMorgan Chase & Co. started coverage on shares of Silk Road Medical in a research report on Monday, April 29th. They issued an “overweight” rating and a $45.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Silk Road Medical in a research report on Monday, April 29th. They set a “buy” rating and a $44.00 target price on the stock. Bank of America started coverage on shares of Silk Road Medical in a research report on Monday, April 29th. They set a “neutral” rating and a $43.00 target price on the stock. They noted that the move was a valuation call. Finally, BMO Capital Markets started coverage on shares of Silk Road Medical in a research report on Monday, April 29th. They set an “outperform” rating and a $40.01 target price on the stock.

Silk Road Medical stock traded down $0.01 during midday trading on Friday, reaching $46.00. The stock had a trading volume of 3,505 shares, compared to its average volume of 143,367. Silk Road Medical has a 52-week low of $30.87 and a 52-week high of $51.50.

Silk Road Medical (NASDAQ:SILK) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($7.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($6.67). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $12.28 million. Sell-side analysts expect that Silk Road Medical will post -1.75 EPS for the current fiscal year.

In related news, major shareholder X Finance L.P. Wp sold 900,000 shares of Silk Road Medical stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $20.00, for a total transaction of $18,000,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.

Read More: How analysts view the yield curve

Get a free copy of the Zacks research report on Silk Road Medical (SILK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.